Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

BACKGROUND: We evaluated the safety and immunogenicity of (i) an intradermal HIV-DNA regimen given with/without intradermal electroporation (EP) as prime and (ii) the impact of boosting with modified vaccinia virus Ankara (HIV-MVA) administered with or without subtype C CN54rgp140 envelope protein a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Viegas, Edna O., Kroidl, Arne, Munseri, Patricia J., Missanga, Marco, Nilsson, Charlotta, Tembe, Nelson, Bauer, Asli, Joachim, Agricola, Joseph, Sarah, Mann, Philipp, Geldmacher, Christof, Fleck, Sue, Stöhr, Wolfgang, Scarlatti, Gabriella, Aboud, Said, Bakari, Muhammad, Maboko, Leonard, Hoelscher, Michael, Wahren, Britta, Robb, Merlin L., Weber, Jonathan, McCormack, Sheena, Biberfeld, Gunnel, Jani, Ilesh V., Sandström, Eric, Lyamuya, Eligius
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6264478/
https://ncbi.nlm.nih.gov/pubmed/30496299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0206838
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados